Nanobiotix S.A. (NBTX)
| Market Cap | 689.22M |
| Revenue (ttm) | 76,000 |
| Net Income (ttm) | -53.46M |
| Shares Out | 15.55M |
| EPS (ttm) | -3.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $19.00 |
| Previous Close | $18.75 |
| Change ($) | 0.25 |
| Change (%) | 1.33% |
| Day's Open | 19.73 |
| Day's Range | 19.00 - 20.63 |
| Day's Volume | 28,629 |
| 52-Week Range | 15.95 - 20.63 |
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company”), a clinical-stage biotechnology company focused on developing ...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX (Paris:NANO) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company focused on developing first-in-clas...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – Nasdaq: NBTX – the ‘‘Company''), a clinical-stage nanomedicine company pioneering new appr...
PARIS--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company''), a clinical-stage nanomedicine company pioneering new approaches to t...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company''), a clinical-stage nanomedicine company pioneering n...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company''), a clinical-stage nanomedicine company pioneering n...
About NBTX
Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated... [Read more...]
| Industry Biotechnology | IPO Date Dec 11, 2020 |
| CEO Laurent Levy | Employees 98 |
| Stock Exchange NASDAQ | Ticker Symbol NBTX |
Financial Performance
In 2019, Nanobiotix's revenue was 2.54 million, a decrease of -26.96% compared to the previous year's 3.48 million. Losses were -50.92 million, 67.8% more than in 2018.